These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 33245213)

  • 1. Improving Cancer Immunotherapy with CRISPR-Based Technology.
    Li Z; Fei T
    Adv Biosyst; 2020 Nov; 4(11):e1900253. PubMed ID: 33245213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management.
    Allemailem KS; Alsahli MA; Almatroudi A; Alrumaihi F; Al Abdulmonem W; Moawad AA; Alwanian WM; Almansour NM; Rahmani AH; Khan AA
    Int J Nanomedicine; 2023; 18():5531-5559. PubMed ID: 37795042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applications and advances of CRISPR-Cas9 in cancer immunotherapy.
    Xia AL; He QF; Wang JC; Zhu J; Sha YQ; Sun B; Lu XJ
    J Med Genet; 2019 Jan; 56(1):4-9. PubMed ID: 29970486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
    Mollanoori H; Shahraki H; Rahmati Y; Teimourian S
    Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The application of CRISPR-Cas9 genome editing tool in cancer immunotherapy.
    Wu HY; Cao CY
    Brief Funct Genomics; 2019 Mar; 18(2):129-132. PubMed ID: 29579146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor immunology CRISPR screening: present, past, and future.
    Dong MB; Tang K; Zhou X; Zhou JJ; Chen S
    Trends Cancer; 2022 Mar; 8(3):210-225. PubMed ID: 34920978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The CRISPR System and Cancer Immunotherapy Biomarkers.
    Balan V; Wang J
    Methods Mol Biol; 2020; 2055():301-322. PubMed ID: 31502158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR/Cas: From Tumor Gene Editing to T Cell-Based Immunotherapy of Cancer.
    Azangou-Khyavy M; Ghasemi M; Khanali J; Boroomand-Saboor M; Jamalkhah M; Soleimani M; Kiani J
    Front Immunol; 2020; 11():2062. PubMed ID: 33117331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances and applications of CRISPR-Cas9 in cancer immunotherapy.
    Liu Z; Shi M; Ren Y; Xu H; Weng S; Ning W; Ge X; Liu L; Guo C; Duo M; Li L; Li J; Han X
    Mol Cancer; 2023 Feb; 22(1):35. PubMed ID: 36797756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRISPR technology for immuno-oncology applications.
    Wang J; Balan V; Marincola F
    Methods Enzymol; 2020; 635():251-266. PubMed ID: 32122549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic abrogation of immune checkpoints in antigen-specific cytotoxic T-lymphocyte as a potential alternative to blockade immunotherapy.
    Zhang C; Peng Y; Hublitz P; Zhang H; Dong T
    Sci Rep; 2018 Apr; 8(1):5549. PubMed ID: 29615718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR-Based Approaches for Cancer Immunotherapy.
    Malla RR; Middela K
    Crit Rev Oncog; 2023; 28(4):1-14. PubMed ID: 38050977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Advances in application of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 system in stem cells research].
    Sun SJ; Huo JH; Geng ZJ; Sun XY; Fu XB
    Zhonghua Shao Shang Za Zhi; 2018 Apr; 34(4):253-256. PubMed ID: 29690746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical applications of CRISPR-based genome editing and diagnostics.
    Foss DV; Hochstrasser ML; Wilson RC
    Transfusion; 2019 Apr; 59(4):1389-1399. PubMed ID: 30600536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy.
    Ghaffari S; Khalili N; Rezaei N
    J Exp Clin Cancer Res; 2021 Aug; 40(1):269. PubMed ID: 34446084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRISPR technology: The engine that drives cancer therapy.
    Zhang M; Eshraghian EA; Jammal OA; Zhang Z; Zhu X
    Biomed Pharmacother; 2021 Jan; 133():111007. PubMed ID: 33227699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delivery of CRISPR/Cas systems for cancer gene therapy and immunotherapy.
    Song X; Liu C; Wang N; Huang H; He S; Gong C; Wei Y
    Adv Drug Deliv Rev; 2021 Jan; 168():158-180. PubMed ID: 32360576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular and therapeutic effect of CRISPR in treating cancer.
    Rodrigo S; Senasinghe K; Quazi S
    Med Oncol; 2023 Jan; 40(2):81. PubMed ID: 36650384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of CRISPR/Cas9-Edited PD-1/PD-L1 on Tumor Immunity and Immunotherapy.
    Xu Y; Chen C; Guo Y; Hu S; Sun Z
    Front Immunol; 2022; 13():848327. PubMed ID: 35300341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retroviral Vectors for Cancer Gene Therapy.
    Schambach A; Morgan M
    Recent Results Cancer Res; 2016; 209():17-35. PubMed ID: 28101685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.